Skystar Bio-Pharmaceutical Co (FRA:GNJC) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2014)

View and export this data going back to . Start your Free Trial

What is Skystar Bio-Pharmaceutical Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Skystar Bio-Pharmaceutical Co's long-term debt to total assests ratio for the quarter that ended in Sep. 2014 was 0.00.

Skystar Bio-Pharmaceutical Co's long-term debt to total assets ratio stayed the same from Sep. 2013 (0.00) to Sep. 2014 (0.00).

Skystar Bio-Pharmaceutical Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Skystar Bio-Pharmaceutical Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Skystar Bio-Pharmaceutical Co LT-Debt-to-Total-Asset Chart

Skystar Bio-Pharmaceutical Co Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

Skystar Bio-Pharmaceutical Co Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Skystar Bio-Pharmaceutical Co LT-Debt-to-Total-Asset Calculation

Skystar Bio-Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2013 is calculated as

LT Debt to Total Assets (A: Dec. 2013 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2013 )	/	Total Assets (A: Dec. 2013 )
	=	0	/	99.443
	=	0.00

Skystar Bio-Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2014 is calculated as

LT Debt to Total Assets (Q: Sep. 2014 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2014 )	/	Total Assets (Q: Sep. 2014 )
	=	0	/	133.168
	=	0.00

Skystar Bio-Pharmaceutical Co (FRA:GNJC) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Skystar Bio-Pharmaceutical Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Skystar Bio-Pharmaceutical Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Skystar Bio-Pharmaceutical Co (FRA:GNJC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Skystar Bio-Pharmaceutical Co (FRA:GNJC) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

No. 48 Keji Road, 4/F Building B, Chuangye Square, Gaoxin District, Xian, Shaanxi Province, CHN

Website

http://www.skystarbio-pharmaceutical.com

Skystar Bio-Pharmaceutical Co is a holding company. Through its subsidiaries, it is engaged in the research, development, production, marketing, and sales of veterinary healthcare and medical care products in the People's Republic of China. The company provides individually packaged animal wellness and pharmaceutical products for retail sale. It generates revenue from the sales of four product lines namely, veterinary medications, micro-organism, feed additives, and vaccines. The firm develops, manufactures, packages and distributes vaccines; Western medicines, Traditional Chinese Medicine; topicals, supplements, probiotics; diagnostic kits and animal nutrition supplements for poultry, livestock, marine aquaculture and domesticated pets.

Skystar Bio-Pharmaceutical Co (FRA:GNJC) Headlines

No Headlines